Clinical characteristics of avascular necrosis in patients with Behçet disease: a case series and literature review.
Avascular necrosis
Behçet disease
Corticosteroid
Multifocal involvement
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
01
11
2018
accepted:
07
12
2018
pubmed:
19
12
2018
medline:
28
12
2019
entrez:
19
12
2018
Statut:
ppublish
Résumé
Avascular necrosis (AVN), also known as osteonecrosis, is characterized by death of the osteocytes due to inadequate blood supply caused by various mechanisms. The hip is the most common affected joint followed by knee. Incidence of AVN in rheumatic diseases is variable and high corticosteroid (CS) therapy is a known major risk factor for development of AVN. Data on the AVN in Behçet disease (BD) are limited. The purpose of this study is to examine the clinical and treatment characteristics of BD patients with diagnosis of AVN. Retrospective medical records of 337 BD patients were reviewed. Nine BD patients with AVN were detected. The clinical data of these patients with AVN have been reviewed. All patients had MRI of the symptomatic joints compatible with AVN. All of the nine patients who were diagnosed with AVN were male. Median duration of BD was 7 years. Median time between diagnosis of BD and detection of AVN was 3 years (1-16 years). Multiple joints were involved in seven patients. Six patients had bilateral knee AVN. Six patients had vascular BD. The median time interval between initial CS dose and AVN development was 24 months (range = 2-100). The median highest daily CS dose was 64 mg/day (range = 32-80) and median cumulative CS dose prior to AVN was 18 g. All of patients had intravenous pulse steroids. CS treatment, smoking and vascular involvement may predispose to AVN in patients with BD. According to this cohort, AVN in BD frequently tended to be in the knee joint and bilateral.
Identifiants
pubmed: 30560445
doi: 10.1007/s00296-018-4224-9
pii: 10.1007/s00296-018-4224-9
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
153-159Références
World J Orthop. 2015 Sep 18;6(8):590-601
pubmed: 26396935
J Eur Acad Dermatol Venereol. 2019 Feb;33(2):416-420
pubmed: 30394611
Clin Exp Rheumatol. 2001 Sep-Oct;19(5 Suppl 24):S51-4
pubmed: 11760400
Nihon Seikeigeka Gakkai Zasshi. 1994 May;68(5):367-78
pubmed: 8051464
Hip Int. 2011 Jul-Aug;21(4):385-92
pubmed: 21786259
Clin Orthop Relat Res. 1988 Sep;(234):115-23
pubmed: 3409564
Rheumatology (Oxford). 2011 Nov;50(11):2023-8
pubmed: 21865285
Clin Exp Rheumatol. 2010 Jul-Aug;28(4 Suppl 60):S95-6
pubmed: 20868582
Chin Med J (Engl). 2015 Nov 5;128(21):2843-50
pubmed: 26521779
Nouv Presse Med. 1981 May 9;10(21):1707-10
pubmed: 7232160
Lancet. 1990 May 5;335(8697):1078-80
pubmed: 1970380
BMJ Open. 2017 Jul 21;7(7):e016788
pubmed: 28733303
Rev Neurol (Paris). 2017 Mar;173(3):171-172
pubmed: 28341141
J Clin Rheumatol. 2008 Jun;14(3):169-74
pubmed: 18525438
Pak J Med Sci. 2017 May-Jun;33(3):770-772
pubmed: 28811813
Medicine (Baltimore). 2003 Jan;82(1):60-76
pubmed: 12544711
N Engl J Med. 1992 May 28;326(22):1473-9
pubmed: 1574093
Br J Rheumatol. 1998 Aug;37(8):895-900
pubmed: 9734682
J Rheumatol. 1997 Apr;24(4):654-62
pubmed: 9101497
Ann Rheum Dis. 2001 Dec;60(12):1145-8
pubmed: 11709458
Neth J Med. 1991 Oct;39(3-4):153-7
pubmed: 1791877
Ann Rheum Dis. 2006 Jun;65(6):785-90
pubmed: 16269429
Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S3-14
pubmed: 26487500
Orthopade. 2005 Feb;34(2):171-83; quiz 184
pubmed: 15714357
Int J Dermatol. 2003 May;42(5):346-51
pubmed: 12755969
Arch Intern Med. 1978 May;138(5):750-4
pubmed: 646538